

Conduent NYSE: CNDT

Investor Presentation



Cautionary Statements



Forward-Looking Statements

This report contains "forward-looking statements" that involve risks and uncertainties. These statements can be identified by the fact that they do not relate strictly to historical or current facts, but rather are based on current expectations, estimates, assumptions and projections about the business process outsourcing industry and our business and financial results. Forward-looking statements often include words such as "anticipates," "expirates," "expects," "projects," "intends," "plans," "believes" and words and terms of similar substance in connection with discussions of future operating or financial performance. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. Our actual results may vary materially from those expressed or implied in our forward-looking statements. Accordingly, undue reliance should not be placed on any forward-looking statement made by us or on our behalf. Important factors that could cause our actual results to differ materially from those in our forward-looking statements include, but are not limited to:

- termination rights contained in our government contracts;
- our ability to renew commercial and government contracts awarded through competitive bidding processes;
- our ability to recover capital and other investments in connection with our contracts;
- our ability to attract and retain necessary technical personnel and qualified subcontractors;
- our ability to deliver on our contractual obligations properly and on time:
- competitive pressures:
- our significant indebtedness;
- changes in interest in outsourced business process services;
- our ability to obtain adequate pricing for our services and to improve our cost structure;
- claims of infringement of third-party intellectual property rights;
- the failure to comply with laws relating to individually identifiable information, and personal health information and laws relating to processing certain financial transactions, including payment card transactions and debit or credit card transactions;
- breaches of our security systems and service interruptions;
- our ability to estimate the scope of work or the costs of performance in our contracts;
- our ability to collect our receivables for unbilled services;
- a decline in revenues from or a loss or failure of significant clients:
- fluctuations in our non-recurring revenue:
- our failure to maintain a satisfactory credit rating;
- our ability to attract and retain key employees:
- increases in the cost of telephone and data services or significant interruptions in such services;
- our failure to develop new service offerings;
- our ability to receive dividends or other payments from our subsidiaries:
- changes in tax and other laws and regulations;
- changes in government regulation and economic, strategic, political and social conditions;

obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements, whether as a result of new information, subsequent events or otherwise.

- changes in U.S. GAAP or other applicable accounting policies; and
- other factors that are set forth in the "Risk Factors" section, the "Legal Proceedings" section, the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section and other sections of our Annual Report on Form

 10 K or well on in our Quarterly Reports on Form 10 Q and Current Reports on Form 20 Killed with the Societies and Evabours Commission.

 11 K or well on in our Quarterly Reports on Form 10 Q and Current Reports on Form 20 Killed with the Societies and Evabours Commission.

 12 K or well on in our Quarterly Reports on Form 10 Q and Current Reports on Form 20 Killed with the Societies and Evabours Commission.

 13 K or well on in our Quarterly Reports on Form 10 Q and Current Reports on Form 20 Killed with the Societies and Evabours Commission.

10-K, as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission.

We caution you that the foregoing list of important factors may not contain all of the material factors that are important to you. Any forward-looking statements made by us in this presentation speak only as of the date on which they are made. We are under no

Non-GAAP Financial Measures

We have reported our financial results in accordance with U.S. generally accepted accounting principles (GAAP). In addition, we have discussed our financial results using non-GAAP measures. We believe these non-GAAP measures allow investors to better understand the trends in our business and to better understand and compare our results. Accordingly, we believe it is necessary to adjust several reported amounts, determined in accordance with GAAP, to exclude the effects of certain items as well as their related tax effects. Management believes that these non-GAAP financial measures provide an additional means of analyzing the current periods' results against the corresponding prior periods' results. However, these non-GAAP financial measures should be viewed in addition to, and not as a substitute for, the Company's reported results prepared in accordance with U.S. GAAP. Our non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable U.S. GAAP measures and should be read only in conjunction with our Condensed Consolidated Financial Statements prepared in accordance with U.S. GAAP. Our management regularly uses our supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions, and providing such non-GAAP financial measures to investors allows for a further level of transparency as to how management reviews and evaluates our business results and trends. These non-GAAP measures are footnoted, where applicable, in each slide herein.

2





Leader in business process services delivering seamless, mission-critical interactions for businesses, governments and their constituents globally



¹Please refer to Appendix for Non-GAAP reconciliations of adjusted EBITDA/margin, and adjusted EPS Revenue, Adjusted EBITDA reflect FY2016; renewal and teammate count as of June 30, 2017. Market size and growth rate source: Conduent Internal Data; 2015 Nelson Hall BPO market forecast



Large and Growing Addressable Market

Strong Client Base

- 76 of Fortune 100 companies
- 27 countries rely on our transportation solutions
- All top 20 managed U.S. healthcare plans
- 9 out of 10 global pharmaceutical companies
- 4 of top 5 global mobile phone manufacturers
- 3 out of 5 U.S. mobile phone providers
- 5 out of 10 largest global banks

Market Size (\$B, 2016)



Commercial Business



Industries-



High-Tech, Industrial & Retail

Communications & Media

Banking, Insurance & Capital Markets

Healthcare Payer

Healthcare Provider & Pharma

Offerings-



Commercial Segment




Segment Highlights

- Revenue decline includes impact from strategic exits, lost business and volume headwinds
- Strategic transformation savings offset by Customer Experience performance, revenue decline, investments and dis-synergies

(\$ in millions) Q2'16 Q2 '17 Yr/Yr Revenue \$939 \$876 (7%)Segment Profit \$35 \$32 (9%)Segment Margin % 3.7% 3.7% 0 bps Segment AEBITDA1 \$76 \$75 (1%)Segment AEBITDA Margin¹ % 8.1% 8.6% 50 bps

Revenue By Vertical (% of segment total)



Quarterly Revenue and Profit



Segment Profit	\$26	\$35	\$42	\$48	\$29	\$32
AEBITDA ¹	\$71	\$76	\$85	\$81	\$70	\$75

Revenue (\$ in M)

% Segment Margin

Public Sector Business



Clients and Constituents



Who we serve



Business Units and Offerings

Transportation



Federal, State & Local



Healthcare



Medical Administration Fiscal Agent

Pharmacy Administration

Management & Long Term Care

Payments



Child Support

Citizen Entitlement Benefits

Payments

Card Services


Public Sector Segment



Segment Highlights

- Revenue headwinds as expected due to prior year contract losses in Government Healthcare, State & Local and Payments
- Transportation revenue flat yr/yr as new business ramp was offset by volume and price declines
- Segment profit pressure driven by revenue decline as well as investments and dis-synergies


Quarterly Revenue and Profit



% Segment Margin

(\$ in millions)	Q2 '16	Q2 '17	Yr/Yr
Revenue	\$579	\$540	(7%)
Segment Profit	\$78	\$59	(24%)
Segment Profit Margin %	13.5%	10.9%	(260 bps)
Segment AEBITDA ¹	\$104	\$83	(20%)
Segment AEBITDA Margin ¹ %	18.0%	15.4%	(260 bps)

Revenue By Business (% of segment total)



Revenue (\$ in M)

Other Segment





Segment Highlights

- Revenue down 16% yr/yr as we reduce exposure in Education and Health Enterprise
- Yr/Yr profit improvement largely driven by prior year remediation work in Education and improved Health Enterprise results

(\$ in millions)	Q2 '16	Q2 '17	Yr/Yr	
Revenue	\$95	\$80	(16%)	
Segment Loss ¹	(\$36)	(\$3)	NM	
Segment Margin %	(37.9%)	(3.8%)	NM	
Segment AEBITDA ¹	(\$32)	(\$1)	NM	
Segment AEBITDA Margin ¹ %	(33.7%)	(1.3%)	NM	

Revenue By Vertical (% of segment total)





Revenue in \$M

Strategic Transformation




Progress and Outlook

- Gaining momentum across the board; expect to achieve 2017 target
- Solid pipeline of cost initiatives provides comfort in expected 2017-2018 savings targets
- Significant progress in IT, finance, real estate and HR
- Customer Experience turnaround slower than anticipated due to legacy model and contractual difficulties

(\$ in millions)	Expected Savings
FY 2017 Cumulative Target	~\$430
FY 2018 Cumulative Target	~\$700

Sources of Expected Transformation Savings Through FY 2018




Portfolio Review



Core vs. Non-Core Update

- Completed sale of Global Mobility business in July
 - ~\$13M annual revenue, negative (~15%) operating margin
 - No impact to 2017 guidance
- Currently \$250 to \$500M of revenue under review for divestiture
 - Will update guidance as appropriate
- Addressing long-tail through run-off
 - Assumed in guidance





Reaffirmed 2017 Guidance

	FY 2016	FY 2017E
Revenue	\$6,408M	Down 4.5-6.5% (CC ¹)
Adjusted EBITDA ²	\$635M	Up 5-6%
Free Cash Flow	(\$81M)	20-30% of Adj. EBITDA ²

¹ Constant currency based on foreign exchange rates as of the prior-year period

² Please refer to Appendix "Non-GAAP Outlook" for certain non-GAAP information concerning outlook



Financials



Q2 2017 Earnings

(in millions)	Q2 2016	Q2 2017	<u>B/(W)</u> <u>Yr/Yr</u>	Comments
Revenue	\$1,613	\$1,496	(\$117)	Portfolio actions, business run-off and contract losses
Gross margin	15.8%	16.2%	40 bps	Ctratagia transformation
SG&A	170	153	\$17	Strategic transformation
Adjusted operating income ¹	77	88	\$11	
Adjusted operating margin ¹	4.8%	5.9%	110 bps	
Adjusted EBITDA ¹	\$148	\$157	\$9	
Adjusted EBITDA margin ¹	9.2%	10.5%	130 bps	
Amortization of intangible assets	62	61	1	
Restructuring and related costs	23	36	(13)	Facility closures and employee actions
Interest expense ²	11	34	(23)	
Separation costs	16	1	15	
(Gain) on sale of asset	_	(24)	24	Dallas site sale
Other net expense (income)	(1)	(10)	9	Favorable legal settlement
Pretax loss	(34)	(11)	23	
GAAP tax (benefit) rate	(70.6%)	(63.6%)		
GAAP net loss	(\$10)	(\$4)	\$6	
GAAP EPS loss from continuing operations	(\$0.05)	(\$0.03)	\$0.02	
Adjusted net income ¹	\$63	\$36	(\$27)	
Adjusted tax rate ¹	4.5%	33.3%		Prior year period tax reserve release
Adjusted EPS ¹	\$0.30	\$0.16	(\$0.14)	

¹Please refer to Appendix for Non-GAAP reconciliations of adjusted operating income/margin, adjusted EBITDA/margin, adjusted tax rate, adjusted net income and adjusted EPS ²Q2 2016 Interest expense includes \$10M in Related-party interest



Cash Flow

(in millions)	Q2 2016	Q2 2017
Net loss	(\$10)	(\$4)
Depreciation & amortization	134	130
Stock-based compensation	6	12
Restructuring payments	(13)	(13)
Restructuring and related costs	20	34
Change for income tax assets and liabilities	(51)	7
Change in accounts receivable	28	41
Change in other net working capital	(195)	(86)
Other ¹	20	(54)
Operating Cash Flow	(\$61)	\$67
Purchase of LB&E ² and other	(36)	(27)
Proceeds from sales of LB&E	_	33
Net proceeds from investments, net of adjustments	3	_
Net payments on related party notes receivable	3	_
Other investing	(1)	_
Investing Cash Flow	(\$31)	\$6
Cash from Financing	\$110	(\$19)
Effect of exchange rates on cash and cash equivalents	(1)	_
Beginning cash and cash equivalents	143	255
Change in cash and cash equivalents	17	54
Ending Cash and Cash Equivalents	\$160	\$309
Memo: Free Cash Flow ³	(\$97)	\$69

Q2 2017 Commentary:

- Better than expected cash flow driven by improved working capital management and operational focus
- Proceeds from gain on sale of asset (Dallas) resulted in \$33M cash
- Expect to meet full-year 2017 free cash flow guidance

Includes deferred tax expense, gain (loss) investments, amortization of financing costs, contributions to defined benefit pension plans, and Other operating, net

²Includes cost of additions to land, building and equipment (LB&E) and internal use software

Free cash flow is defined as operating cash flow less cost of net additions to land, building and equipment and internal use software as well as cost of capital lease initiations of \$4M for Q2 2017.



Capital Structure Overview

Debt Structure (\$ in millions)

	3/31/2017	6/30/2017
Cash	\$255	\$309
Total Debt ¹	2,121	2,130
Term Loan A ^{2, 5} due 2021	699	719*
Term Loan B ² due 2023	848	846
10.5% Senior Notes due 2024	510	510
Revolving Credit Facility ³ due 2021	70	70
Capital Leases	48	46
Current net leverage ratio ⁴	2.9x	2.8x

Credit Metrics / Statistics

Expected annual interest expense	~\$140M
Preferred dividend (annually)	~\$10M
Target net leverage ratio	<2.5x
Average remaining maturity on outstanding debt	~6 years

Key Messages

- Cash balance up over \$50M qtr/qtr
- No additional use of revolver in the quarter
- Still targeting to reduce leverage ratio over time with Adjusted EBITDA⁶ growth and required debt payments

^{*}Reflects appreciation of the EUR; there was no incremental borrowing on the Term Loan A in Q2 2017

¹ Total debt excludes deferred financing costs

² Revolving credit facility and Term Loan A interest rate is Libor + 225 bps; Term Loan B is Libor + 400 bps effective April 7, 2017

³ \$663M of available capacity under Revolving Credit Facility as of 6/30/2017

⁴ Net debt (total debt less cash) divided by TTM adjusted EBITDA

⁵ Includes initial EUR 260M borrowing converted at end of quarter exchange rates

⁶ Please refer to Appendix for Non-GAAP reconciliations of adjusted operating income/margin, adjusted EBITDA/margin, adjusted tax rate, adjusted net income and adjusted EPS

Appendix

Signings & Renewal Rate



(\$ in millions)	<u>Q1' 16</u>	<u>Q2' 16</u>	<u>Q3' 16</u>	<u>Q4' 16</u>	<u>Q1' 17</u>	<u>Q2' 17</u>
Total Contract Value	\$1,488	\$2,158	\$1,546	\$1,660	\$931	\$1,244
New Business	643	527	633	724	530	657
Renewals	845	1,631	913	936	401	587
Annual Recurring Revenue Signings	\$129	\$112	\$166	\$182	\$143	\$130
Non-Recurring Revenue Signings	\$83	\$140	\$104	\$111	\$92	\$109
Renewal rate	89%	88%	89%	85%	92%	89%
Renewal rate (previous methodology)	89%	84%	83%	82%	80%	76%

2017 Modeling Considerations



Comn	nentary
------	---------

Seasonality

Revenue Q3/Q4 weighted given vertical exposure (Healthcare, Retail)

D&A (excl. amortization of intangibles)

Modest sequential increases in Q3 and Q4

Profitability

Q3/Q4 weighted given seasonality and cost initiatives

Restructuring costs

Still expecting ~\$75M for the full year

Interest Expense

~\$70M for H2; ~\$140M for the full year

Cash Flow

H2 weighted; 2017 FCF guidance unchanged

Capex

~2.0% for the full year given lower-than-expected spend YTD

Other segment

Still expect break-even in 2018; results may be uneven

Long-term targets

Unchanged from December 5, 2016 Investor event

Definitions



H1 = First six months of the year

H2 = Second six months of the year

BICM = Banking, Insurance & Capital Markets

HTIR = High-Tech, Industrial & Retail

TCV = Total contract value

ARR = Annual recurring revenue

NRR = Non-recurring revenue

New Business TCV = Annual recurring revenue signings multiplied by the contract term plus non-recurring revenue signings

Renewal Rate = Annual recurring revenue (ARR) on contracts that are renewed during the period as a percentage of ARR on all contracts for which a renewal decision was made during the period (excluding contracts for which a strategic decision to not renew was made based on risk or profitability).

Revenue productivity = Calculated as trailing-twelve months (TTM) revenue / average quarter-end headcount for last four quarters. Segment calculation excludes corporate headcount.

Non-GAAP Financial Measures



Non-GAAP Financial Measures

We have reported our financial results in accordance with U.S. generally accepted accounting principles (GAAP). In addition, we have discussed our financial results using the non-GAAP measures. We believe these non-GAAP measures allow investors to better understand the trends in our business and to better understand and compare our results. Accordingly, we believe it is necessary to adjust several reported amounts, determined in accordance with U.S. GAAP, to exclude the effects of certain items as well as their related tax effects. Management believes that these non-GAAP financial measures should be viewed in addition to, and not as a substitute for, the Company's reported results prepared in accordance with U.S. GAAP. Our non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable U.S. GAAP measures and should be read only in conjunction with our Condensed Consolidated Financial Statements prepared in accordance with U.S. GAAP. Our management regularly uses our supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions, and providing such non-GAAP financial measures to investors allows for a further level of transparency as to how management reviews and evaluates our business results and trends. These non-GAAP measures are among the primary factors management uses in planning for and forecasting future periods. Compensation of our executives is based in part on the performance of our business based on these non-GAAP measures.

A reconciliation of the following non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP are provided below.

These reconciliations also include the income tax effects for our non-GAAP performance measures in total, to the extent applicable. The income tax effects are calculated under the same accounting principles as applied to our reported pre-tax performance measures under ASC 740, which employs an annual effective tax rate method. The noted income tax effect for our non-GAAP performance measures is effectively the difference in income taxes for reported and adjusted pre-tax income calculated under the annual effective tax rate method. The tax effect of the non-GAAP adjustments was calculated based upon evaluation of the statutory tax treatment and the applicable statutory tax rate in the jurisdictions in which such charges were incurred.

Adjusted Net Income (Loss), Adjusted Earnings per Share and Adjusted Effective Tax Rate.

We make adjustments to Income (Loss) before Income Taxes for the following items, for the purpose of calculating Adjusted Net Income (Loss), Adjusted Earnings per Share and Adjusted Effective Tax Rate:

- Amortization of intangible assets. The amortization of intangible assets is driven by acquisition activity, which can vary in size, nature and timing as compared to other companies within our industry from period to period.
- Restructuring and related costs. Restructuring and related costs include restructuring and asset impairment charges as well as costs associated with our strategic transformation program.
- Separation costs. Separation costs are expenses incurred in connection with the separation from Xerox Corporation into a separate, independent, publicly traded company. These costs primarily relate to third-party investment banking, accounting, legal, consulting and other similar types of services related to the separation transaction, as well as costs associated with the operation of the two companies.
- Other (income) expenses net. Other (income) expenses, net includes losses (gains) on sales of business and assets, currency (gains) losses, net, litigation matters and all other (income) expenses, net.
- NY Medicaid Management Information System (NY MMIS) costs associated with the company not fully completing the State of New York Health Enterprise platform project.
- Health Enterprise (HE charge) associated with not fully completing the Health Enterprise Medical platform implementation projects in California and Montana.
- Gain on sale of asset (2017 only).

Adjusted Operating Income and Operating Margin.

We make adjustments to Costs and Expenses and Margin for the following items (as defined above), for the purpose of calculating Adjusted Operating Income and Adjusted Operating Margin:

- Amortization of intangible assets. The amortization of intangible assets is driven by acquisition activity, which can vary in size, nature and timing as compared to other companies within our industry from period to period.
- Restructuring and related costs. Restructuring and related costs include restructuring and asset impairment charges as well as costs associated with our strategic transformation program.
- Separation costs. Separation costs are expenses incurred in connection with the separation from Xerox Corporation into a separate, independent, publicly traded company. These costs primarily relate to third-party investment banking, accounting, legal, consulting and other similar types of services related to the separation transaction, as well as costs associated with the operation of the two companies.
- Interest expense. Interest expense includes interest on long-term debt and amortization of debt issuance costs.
- Related Party Interest. Interest payments to former parent.
- Other (income) expenses, net. Other (income) expenses, net includes losses (gains) on sales of business and assets, currency (gains) losses, net, litigation matters and all other (income) expenses, net.
- NY MMIS. Costs associated with the company not fully completing the State of New York Health Enterprise platform project.
- HE charge. Costs associated with not fully completing the Health Enterprise Medical platform implementation projects in California and Montana.
- Gain on sale of asset (2017 only).



Non-GAAP Financial Measures

Adjusted EBITDA and EBITDA Margin

We use Adjusted EBITDA as an additional way of assessing certain aspects of our operations that, when viewed with the U.S. GAAP results and the accompanying reconciliations to corresponding U.S. GAAP financial measures, provide a more complete understanding of our on-going business. We also use Adjusted EBITDA to provide additional information that is useful to understand the financial covenants contained in the Company's credit facility and indenture. Adjusted EBITDA represents Income (loss) before Interest. Income Taxes. Depreciation and Amortization adjusted for the following items (which are defined above):

- Goodwill impairment charge. During the fourth quarter 2016, we performed our annual goodwill impairment test which resulted in a non-cash impairment charge of \$935 million in our Commercial Industries reporting unit.
- Restructuring and related costs. Restructuring and related costs include restructuring and asset impairment charges as well as costs associated with our strategic transformation program.
- Separation costs. Separation costs are expenses incurred in connection with the separation from Xerox Corporation into a separate, independent, publicly traded company. These costs primarily relate to third-party investment banking, accounting, legal, consulting and other similar types of services related to the separation transaction, as well as costs associated with the operational separation of the two companies.
- Other (income) expenses, net, Other (income) expenses, net includes losses (gains) on sales of business and assets, currency (gains) losses, net, litigation matters and all other (income) expenses, net,
- NY MMIS / NY MMIS Depreciation. Costs associated with the company not fully completing the State of New York Health Enterprise platform project.
- HE charge. Costs associated with not fully completing the Health Enterprise Medical platform implementation projects in California and Montana.
- Gain on sale of asset (2017 only).

Adjusted EBITDA is not intended to represent cash flows from operations, operating income (loss) or net income (loss) as defined by U.S. GAAP as indicators of operating performance. Management cautions that amounts presented in accordance with Conduent's definition of Adjusted EBITDA may not be comparable to similar measures disclosed by other companies because not all companies calculate Adjusted EBITDA in the same manner.

Adjusted Other Segment Revenue and Profit

We adjusted Other Segment revenue, profit and margin for the NY MMIS and HE charges.

Free Cash Flow

Free Cash Flow is defined as cash flows from operating activities as reported on the consolidated statement of cash flows, less cost of additions to land, buildings and equipment, cost of additions to internal use software, capital lease additions and the gain on sale of an asset in 2017. We use the non-GAAP measure of Free Cash Flow as a criterion of liquidity and performance-based components of employee compensation. We use Free Cash Flow as a measure of liquidity to determine amounts we can reinvest in our core businesses, such as amounts available to make acquisitions, invest in land, buildings and equipment and internal use software, make principal payments on debt. In order to provide a meaningful basis for comparison, we are providing information with respect to our Free Cash Flow reconciled to cash flow provided by operating activities, which we believe to be the most directly comparable measure under U.S. GAAP.

Constant Currency

To better understand trends in our business, we believe that it is helpful to adjust revenue to exclude the impact of changes in the translation of foreign currencies into U.S. Dollars. We refer to this adjusted revenue as "constant currency." Currency impact can be determined as the difference between actual growth rates and constant currency growth rates. This currency impact is calculated by translating the current period activity in local currency using the comparable prior-year period's currency translation rate.

Non-GAAP Outlook

In providing outlook for adjusted EBITDA we exclude certain items which are otherwise included in determining the comparable GAAP financial measure. A description of the adjustments which historically have been applicable in determining adjusted EBITDA are reflected in the table below. We are providing such outlook only on a non-GAAP basis because the Company is unable to predict with reasonable certainty the totality or ultimate outcome or occurrence of these adjustments for the forward-looking period, such as amortization, restructuring, separation costs, NY MMIS, HE charge, and certain other adjusted items, which can be dependent on future events that may not be reliably predicted. Based on past reported results, where one or more of these items have been applicable, such excluded items could be material, individually or in the aggregate, to reported results.



Non-GAAP Reconciliation: Net Income (Loss) & EPS

	Three Months Ended June 30, 2017			Three Months Ended June 30, 2016				
(in millions, except EPS)	Net Income (Loss)		EPS		Net Income (Loss)		EPS	
GAAP as Reported From Continuing Operations	\$	(4)	\$	(0.03)	\$	(10)	\$	(0.05)
Adjustments:								
Amortization of intangible assets		61				62		
NY MMIS		1				_		
Restructuring and related costs		36				23		
Separation costs		1				16		
(Gain) on sale of asset		(24)				_		
Other (income) expenses, net		(10)				(1)		
Less: Income tax adjustments(1)		(25)				(27)		
Adjusted Net Income (Loss) and EPS	\$	36	\$	0.16	\$	63	\$	0.30
(shares) Weighted average common shares								
outstanding Restricted stock and performance				204				203
shares				3				3
8% Convertible preferred stock								5_
Adjusted Weighted Average Shares Outstanding ⁽²⁾				207				211

⁽¹⁾ Reflects the income tax (expense) benefit of the adjustments. Refer to the Effective Tax Rate reconciliation details.

⁽²⁾ Average shares for the 2017 calculation of adjusted EPS exclude 5 million shares associated with our Series A convertible preferred stock and includes the impact of the preferred stock quarterly dividend of \$3 million for the three months ended June 30, 2017. Average shares for the 2016 calculation of adjusted EPS include 5 million shares associated with our Series A convertible preferred stock and excludes the impact of the preferred stock quarterly dividend.



Non-GAAP Reconciliation: Effective Tax Rate

		ree Months Ended June 30, 2017		Three Months Ended June 30, 2016									
(in millions)	ax Income Loss)	Income Tax (Benefit) Expense	Effective Tax Rate	Pr	e-Tax Income (Loss)		Income Tax (Benefit) Expense	Effective Tax Rate					
GAAP as Reported From Continuing Operations	\$ (11)	\$ (7)) (63.6%	\$	(34)	\$	(24)	(70.6%					
Non-GAAP adjustments ⁽¹⁾	 65	25			100		27						
Adjusted ⁽²⁾	\$ 54	\$ 18	33.3%	\$	66	\$	3	4.5%					

⁽¹⁾ Refer to Net Income (Loss) reconciliation for details.

⁽²⁾ The tax impact of Adjusted Pre-Tax Income (Loss) from continuing operations is calculated under the same accounting principles applied to the As Reported Pre-Tax Income under ASC 740, which employs an annual effective tax rate method to the results.

Non-GAAP Reconciliation: Operating Income / Margin



(in millions)	Q2 2017		Q1 2017	Q4 2016	Q3 2016	Q2 2016		Q1 2016
GAAP Revenue From Continuing Operations	\$ 1,496	\$	1,553	\$ 1,514	\$ 1,596	\$ 1,613	\$	1,685
GAAP Pre-tax (Loss) Income From Continuing Operations	(11)		(22)	(1,141)	2	(34)		(54)
GAAP Operating Margin As Reported	(0.7)%	ó	(1.4)%	(75.4)%	0.1%	(2.1)%	5	(3.2)%
GAAP Revenue From Continuing Operations	\$ 1,496	\$	1,553	\$ 1,514	\$ 1,596	\$ 1,613	\$	1,685
NY MMIS adjustment	 _			 83	 	 		
Adjusted Revenue	\$ 1,496	\$	1,553	\$ 1,597	\$ 1,596	\$ 1,613	\$	1,685
GAAP Pre-tax (Loss) Income From Continuing Operations	\$ (11)	\$	(22)	\$ (1,141)	\$ 2	\$ (34)	\$	(54)
Adjustments:								
Goodwill impairment	_		_	935	_	_		_
Amortization of intangible assets	61		61	80	63	62		75
NY MMIS	1		8	161	_	_		_
Restructuring and related costs	36		18	44	8	23		26
HE charge	_		(5)	_	_	_		_
Separation costs	1		5	10	15	16		3
Interest expense	34		36	11	1	1		1
Related party interest	_		_	(4)	10	10		10
Gain on sale of asset	(24)		_	_	_	_		_
Other (income) expenses, net	(10)		(12)	13	(2)	(1)		10
Adjusted Operating Income/Margin	\$ 88	\$	89	\$ 109	\$ 97	\$ 77	\$	71
Adjusted Operating Margin	5.9%		5.7%	6.8%	6.1%	4.8%		4.2%

⁽¹⁾ Pre-Tax Loss and revenue from continuing operations.

Non-GAAP Reconciliation: Adjusted EBITDA



(in millions)	(Q2 2017	Q1 2017	Q4 2016	Q3 2016	Q2 2016	Q1 2016	Full	Year 2016
Reconciliation to Adjusted Revenue									
GAAP Revenue From Continuing Operations	\$	1,496	\$ 1,553	\$ 1,514	\$ 1,596	\$ 1,613	\$ 1,685	\$	6,408
NY MMIS adjustment		_	_	83	_	_	_		_
Adjusted Revenue	\$	1,496	\$ 1,553	\$ 1,597	\$ 1,596	\$ 1,613	\$ 1,685	\$	6,491
Reconciliation to Adjusted EBITDA									
GAAP Net (Loss) Income As Reported From Continuing Operations	\$	(4)	\$ (10)	\$ (951)	\$ 1	\$ (10)	\$ (23)	\$	(983)
Interest expense		34	36	11	1	1	1		14
Related party interest		_	_	(4)	10	10	10		26
Income tax (benefit) expense		(7)	(12)	(190)	1	(24)	(31)		(244)
Depreciation		34	31	36	31	29	32		128
Amortization		96	 94	 159	 104	104	 118		485
EBITDA	\$	153	\$ 139	\$ (939)	\$ 148	\$ 110	\$ 107	\$	(574)
EBITDA Margin		10.2%	9.0%	(62.0)%	9.3%	6.8%	6.4%		(8.8)%
EBITDA	\$	153	\$ 139	\$ (939)	\$ 148	\$ 110	\$ 107	\$	(574)
Adjustments:									
Goodwill impairment		_	_	935	_	_	_		935
Restructuring and related costs		36	18	44	8	23	26		101
Separation costs		1	5	10	15	16	3		44
NY MMIS		1	8	161	_	_	_		161
NY MMIS depreciation		_	_	(52)	_	_	_		(52)
HE charge		_	(5)	_	_	_	_		_
Gain on sale of asset		(24)	_	_	_	_	_		_
Other (income) expenses, net		(10)	 (12)	 13	 (2)	 (1)	 10		20
Adjusted EBITDA	\$	157	\$ 153	\$ 172	\$ 169	\$ 148	\$ 146	\$	635
Adjusted EBITDA Margin		10.5%	9.9%	10.8%	10.6%	9.2%	8.7%		9.8%

⁽¹⁾ Pre-tax loss and Revenue from continuing operations

Non-GAAP Reconciliation: Segment Adjusted EBITDA



(in millions)	G	2 2017	(Q1 2017	Q4 2016	(Q3 2016	(Q2 2016	C	Q1 2016
Commercial Industries											
Segment GAAP revenue	\$	876	\$	923	\$ 936	\$	923	\$	939	\$	1,007
Segment profit	\$	32	\$	29	\$ 48	\$	42	\$	35	\$	26
Depreciation & amortization		43		41	33		43		41		45
Adjusted Segment EBITDA	\$	75	\$	70	\$ 81	\$	85	\$	76	\$	71
Adjusted EBITDA Margin		8.6%		7.6%	8.7%		9.2%		8.1%		7.1%
Public Sector											
Segment GAAP revenue	\$	540	\$	549	\$ 574	\$	584	\$	579	\$	571
Segment profit	\$	59	\$	61	\$ 76	\$	78	\$	78	\$	61
Depreciation & amortization		24		21	26		25		26		25
Adjusted Segment EBITDA	\$	83	\$	82	\$ 102	\$	103	\$	104	\$	86
Adjusted EBITDA Margin		15.4%		14.9%	17.8%		17.6%		18.0%		15.1%
Other Segment											
Segment GAAP revenue	\$	80	3 1 \$	81	\$ 4	\$	89	\$	95	\$	107
NY MMIS charge		_		_	83		_		_		_
Adjusted Segment Revenue	\$	80	\$	81	\$ 87	\$	89	\$	95	\$	107
GAAP Segment loss	\$	(4)	\$	(4)	\$ (173)	\$	(23)	\$	(36)	\$	(16)
NY MMIS charge		1		8	133		_		_		_
HE charge		_		(5)	28		_		_		_
Adjusted Other Segment Loss		(3)		(1)	(12)		(23)		(36)		(16)
Depreciation & amortization		2		2	56		4		4		5
NY MMIS depreciation		_		_	(24)		_		_		_
HE depreciation					(28)						
Adjusted Segment EBITDA	\$	(1)	\$	1	\$ (8)	\$	(19)	\$	(32)	\$	(11)
Adjusted EBITDA Margin		(1.3)%		1.2%	 (9.2)%		(21.3)%		(33.7)%		(10.3)%



Non-GAAP Reconciliation: Other Segment Revenue, Profit (Loss) and Margin

	Thi	ree Mo	Ended		Three Months Ended						Three Months Ended					
		June 30, 2017					March	2017		December 31, 2016						
(in millions)	Re	venue		Loss	Margin	Re	evenue		Loss	Margin	R	evenue		Loss	Margin	
GAAP Other Segment As Reported From Continuing Operations	\$	80	\$	(4)	(5)%	\$	81	\$	(4)	(4.9)%	\$	4	\$	(173)	n/a	
Adjustments:																
NY MMIS		_		1			_		8			83		161		
HE charge		_		_			_		(5)			_		_		
Adjusted Other Segment	\$	80	\$	(3)	(3.8)%	\$	81	\$	(1)	(1.2)%	\$	87	\$	(12)	(13.8)%	

Note: The prior year period results has been adjusted to reflect new segment reporting as of Q1 2017.



Non-GAAP Reconciliation: Free Cash Flow

(in millions)	En	Months ded 30, 2017	Three Months Ended June 30, 2016	Dec	ar Ended ember 31, 2016
Operating Cash Flow	\$	67	\$ (61)	\$	108
Cost of additions to land, buildings & equipment		(20)	(25)		(149)
Cost of additions to internal use software		(7)	(11)		(39)
Proceeds on sale of asset		33	_		_
Vendor financed capital leases		(4)			(1)
Free Cash Flow	\$	69	\$ (97)	\$	(81)

